Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (281-290 of 361) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignanciesAmy J Chien, Julie A Illi, Andrew H Ko, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 resultsMichael J Morris, Arturo Molina, Eric J Small, et al.
JAMA|January 15, 2020
Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical TrialJ Kellogg Parsons, David Zahrieh, James L Mohler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Prostate Cancer and Prostatic Diseases|March 31, 2025
Racial variation in the advanced prostate cancer genomeEmily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, et al.
Future Oncology (London, England)|March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Pageof 37

Showing results (281-290 of 361) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignanciesAmy J Chien, Julie A Illi, Andrew H Ko, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 resultsMichael J Morris, Arturo Molina, Eric J Small, et al.
JAMA|January 15, 2020
Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical TrialJ Kellogg Parsons, David Zahrieh, James L Mohler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Prostate Cancer and Prostatic Diseases|March 31, 2025
Racial variation in the advanced prostate cancer genomeEmily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, et al.
Future Oncology (London, England)|March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Pageof 37